Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 26.32
SUPN's Cash-to-Debt is ranked higher than
61% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. SUPN: 26.32 )
Ranked among companies with meaningful Cash-to-Debt only.
SUPN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 3.48 Max: No Debt
Current: 26.32
Equity-to-Asset 0.64
SUPN's Equity-to-Asset is ranked lower than
53% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SUPN: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
SUPN' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.25  Med: 0.47 Max: 0.68
Current: 0.64
-2.25
0.68
Interest Coverage 13.79
SUPN's Interest Coverage is ranked lower than
73% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. SUPN: 13.79 )
Ranked among companies with meaningful Interest Coverage only.
SUPN' s Interest Coverage Range Over the Past 10 Years
Min: 1  Med: 7.51 Max: N/A
Current: 13.79
Piotroski F-Score: 7
Altman Z-Score: 10.19
Beneish M-Score: -1.96
WACC vs ROIC
15.79%
100.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 28.27
SUPN's Operating Margin % is ranked higher than
87% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. SUPN: 28.27 )
Ranked among companies with meaningful Operating Margin % only.
SUPN' s Operating Margin % Range Over the Past 10 Years
Min: -37851.89  Med: -290.93 Max: 28.27
Current: 28.27
-37851.89
28.27
Net Margin % 42.34
SUPN's Net Margin % is ranked higher than
97% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. SUPN: 42.34 )
Ranked among companies with meaningful Net Margin % only.
SUPN' s Net Margin % Range Over the Past 10 Years
Min: -36285.85  Med: -11.79 Max: 6701.74
Current: 42.34
-36285.85
6701.74
ROE % 57.53
SUPN's ROE % is ranked higher than
98% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. SUPN: 57.53 )
Ranked among companies with meaningful ROE % only.
SUPN' s ROE % Range Over the Past 10 Years
Min: -202.72  Med: -29.46 Max: 65.21
Current: 57.53
-202.72
65.21
ROA % 36.35
SUPN's ROA % is ranked higher than
98% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. SUPN: 36.35 )
Ranked among companies with meaningful ROA % only.
SUPN' s ROA % Range Over the Past 10 Years
Min: -90.03  Med: -8.82 Max: 106.84
Current: 36.35
-90.03
106.84
ROC (Joel Greenblatt) % 1572.64
SUPN's ROC (Joel Greenblatt) % is ranked higher than
99% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. SUPN: 1572.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SUPN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4247.75  Med: -1300.86 Max: 1572.64
Current: 1572.64
-4247.75
1572.64
3-Year Revenue Growth Rate 122.60
SUPN's 3-Year Revenue Growth Rate is ranked higher than
99% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. SUPN: 122.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SUPN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 70.8 Max: 223.7
Current: 122.6
0
223.7
GuruFocus has detected 5 Warning Signs with Supernus Pharmaceuticals Inc $SUPN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SUPN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SUPN Guru Trades in Q2 2016

Robert Bruce 224,581 sh (unchged)
Paul Tudor Jones 14,500 sh (-28.57%)
Joel Greenblatt 12,455 sh (-29.04%)
Steven Cohen 35,600 sh (-96.23%)
» More
Q3 2016

SUPN Guru Trades in Q3 2016

Paul Tudor Jones 14,800 sh (+2.07%)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Robert Bruce 164,581 sh (-26.72%)
» More
Q4 2016

SUPN Guru Trades in Q4 2016

Steven Cohen 1,900 sh (New)
Paul Tudor Jones 27,577 sh (+86.33%)
Robert Bruce 164,581 sh (unchged)
» More
Q1 2017

SUPN Guru Trades in Q1 2017

Joel Greenblatt 102,001 sh (New)
Jeremy Grantham 8,200 sh (New)
Chuck Royce 130,000 sh (New)
Steven Cohen Sold Out
Robert Bruce 64,581 sh (-60.76%)
Paul Tudor Jones 10,548 sh (-61.75%)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:HZNP, OTCPK:EVTCY, NAS:RDUS, NAS:PCRX, NAS:PAHC, OTCPK:SWPIF, NAS:EGRX, NYSE:DPLO, NAS:IPXL, NAS:MNTA, OTCPK:KHTRF, OTCPK:NPPNY, OTCPK:TWMJF, NAS:SGYP, NAS:INNL, NAS:IRWD, NAS:HRTX, NYSE:LCI, NAS:ENDP, NAS:AMPH » details
Traded in other countries:S49.Germany,
Headquarter Location:USA
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Supernus Pharmaceuticals Inc was incorporated in Delaware on March 30, 2005. The Company is a specialty pharmaceutical company engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has other proprietary product candidates in clinical development that address the psychiatry market. The Company is developing multiple product candidates in psychiatry to address the unmet medical needs and market opportunities in impulsive aggression across several areas including attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder, and ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR. Oxtellar XR is indicated for adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age and Trokendi XR is indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures, and as adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures or with seizures associated with Lennox-Gastaut syndrome. Its psychiatry product candidates include ADHD, SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). ADHD is a common CNS disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity; and it develops SPN-810 (molindone hydrochloride) as a treatment for impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment. The Company has a portfolio of drug development technologies consisting of platforms including Microtrol, Solutrol and EnSoTrol. It is utilized to create nine marketed products, including Trokendi XR and Oxtellar XR, as well as other product candidates SPN-810 and SPN-812. The Company markets its products in the United States through its specialty sales force. The Company is subject to regulation by FDA, federal and state government authorities. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.

Top Ranked Articles about Supernus Pharmaceuticals Inc

Supernus to Host First Quarter 2017 Earnings Conference Call
Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents
Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation
ROCKVILLE, Md., March 07, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a binding term sheet with Actavis Laboratories, FL, Inc. et al. (collectively, “Actavis”, now a subsidiary of Teva Pharmaceuticals Industries, Ltd.) involving the ongoing patent litigation regarding Actavis’ Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus’ Trokendi XR® (extended-release topiramate) capsules.  The binding term sheet permits Actavis to begin selling a generic version of Trokendi XR® on January 1, 2023, or earlier under certain circumstances.  The binding term sheet will be submitted to the applicable governmental agencies.
Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR®.  Patent protection for Trokendi XR® expires no earlier than 2027.Supernus is represented by attorneys from Haug Partners LLP and its corporate counsel, Saul Ewing LLP.About Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.Forward Looking StatementsThis press release contains forward-looking statements regarding the Company’s ability to defend and enforce its intellectual property rights covering Trokendi XR®. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, the ability of Supernus to finance potential litigation and to prevail in any such proceeding to successfully defend its intellectual property rights. For a further description of these and other risks facing the Company, please see the risk factors described in the Company’s 2015 Annual Report Form 10-K/A that was filed with the United States Securities and Exchange Commission on January 20, 2017 under the caption “Risk Factors”.  Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as may be required by law.
Contact:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
301-838-2591

Or

Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]

Read more...
Supernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation

ROCKVILLE, Md., March 06, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that it has entered into a settlement agreement with Zydus Pharmaceutical (USA), Inc. and Cadila Healthcare Limited (collectively, “Zydus”) involving the ongoing patent litigation regarding Zydus’ Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus’ Trokendi XR® (extended-release topiramate) capsules.  The settlement agreement permits Zydus to begin selling a generic version of Trokendi XR® on January 1, 2023, or earlier under certain circumstances.  The agreement will be submitted to the applicable governmental agencies.
Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR®.  Patent protection for Trokendi XR® expires no earlier than 2027. Supernus is represented by attorneys from Haug Partners LLP and its corporate counsel, Saul Ewing LLP. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD. Forward Looking Statements This press release contains forward-looking statements regarding the Company’s ability to defend and enforce its intellectual property rights covering Trokendi XR®. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, the ability of Supernus to finance potential litigation and to prevail in any such proceeding to successfully defend its intellectual property rights. For a further description of these and other risks facing the Company, please see the risk factors described in the Company’s 2015 Annual Report Form 10-K/A that was filed with the United States Securities and Exchange Commission on January 20, 2017 under the caption “Risk Factors”.  Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as may be required by law.
Contact:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
301-838-2591

Or

Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]


Read more...

Ratios

vs
industry
vs
history
PE Ratio 18.88
SUPN's PE Ratio is ranked higher than
75% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. SUPN: 18.88 )
Ranked among companies with meaningful PE Ratio only.
SUPN' s PE Ratio Range Over the Past 10 Years
Min: 0.13  Med: 42.35 Max: 235.67
Current: 18.88
0.13
235.67
PE Ratio without NRI 18.88
SUPN's PE Ratio without NRI is ranked higher than
75% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. SUPN: 18.88 )
Ranked among companies with meaningful PE Ratio without NRI only.
SUPN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.37  Med: 47.28 Max: 235.67
Current: 18.88
11.37
235.67
Price-to-Owner-Earnings 14.52
SUPN's Price-to-Owner-Earnings is ranked higher than
78% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. SUPN: 14.52 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SUPN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.56  Med: 33.35 Max: 172.44
Current: 14.52
9.56
172.44
PB Ratio 8.29
SUPN's PB Ratio is ranked lower than
85% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. SUPN: 8.29 )
Ranked among companies with meaningful PB Ratio only.
SUPN' s PB Ratio Range Over the Past 10 Years
Min: 3.23  Med: 7.33 Max: 18.53
Current: 8.29
3.23
18.53
PS Ratio 7.75
SUPN's PS Ratio is ranked lower than
76% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SUPN: 7.75 )
Ranked among companies with meaningful PS Ratio only.
SUPN' s PS Ratio Range Over the Past 10 Years
Min: 3.77  Med: 7.01 Max: 157
Current: 7.75
3.77
157
Price-to-Free-Cash-Flow 21.75
SUPN's Price-to-Free-Cash-Flow is ranked lower than
52% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. SUPN: 21.75 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SUPN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.51  Med: 24.07 Max: 82.21
Current: 21.75
15.51
82.21
Price-to-Operating-Cash-Flow 21.34
SUPN's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. SUPN: 21.34 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SUPN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.96  Med: 22.5 Max: 76.29
Current: 21.34
14.96
76.29
EV-to-EBIT 24.97
SUPN's EV-to-EBIT is ranked lower than
66% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. SUPN: 24.97 )
Ranked among companies with meaningful EV-to-EBIT only.
SUPN' s EV-to-EBIT Range Over the Past 10 Years
Min: -72.8  Med: -2.3 Max: 96
Current: 24.97
-72.8
96
EV-to-EBITDA 23.96
SUPN's EV-to-EBITDA is ranked lower than
75% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. SUPN: 23.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
SUPN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -90.8  Med: -2.3 Max: 88.7
Current: 23.96
-90.8
88.7
Current Ratio 1.83
SUPN's Current Ratio is ranked lower than
61% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. SUPN: 1.83 )
Ranked among companies with meaningful Current Ratio only.
SUPN' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.87 Max: 7.26
Current: 1.83
1.51
7.26
Quick Ratio 1.59
SUPN's Quick Ratio is ranked lower than
55% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. SUPN: 1.59 )
Ranked among companies with meaningful Quick Ratio only.
SUPN' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.65 Max: 7.26
Current: 1.59
1.49
7.26
Days Inventory 468.77
SUPN's Days Inventory is ranked lower than
96% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. SUPN: 468.77 )
Ranked among companies with meaningful Days Inventory only.
SUPN' s Days Inventory Range Over the Past 10 Years
Min: 447.46  Med: 608.33 Max: 1372.72
Current: 468.77
447.46
1372.72
Days Sales Outstanding 62.14
SUPN's Days Sales Outstanding is ranked higher than
54% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. SUPN: 62.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
SUPN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.71  Med: 69.26 Max: 16387.12
Current: 62.14
2.71
16387.12
Days Payable 143.06
SUPN's Days Payable is ranked higher than
93% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. SUPN: 143.06 )
Ranked among companies with meaningful Days Payable only.
SUPN' s Days Payable Range Over the Past 10 Years
Min: 118.1  Med: 216.12 Max: 1038.8
Current: 143.06
118.1
1038.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.40
SUPN's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. SUPN: -7.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SUPN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -199.2  Med: -12.2 Max: 0
Current: -7.4
-199.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 50.81
SUPN's Price-to-Net-Current-Asset-Value is ranked lower than
95% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. SUPN: 50.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SUPN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 15.35 Max: 122.18
Current: 50.81
0
122.18
Price-to-Tangible-Book 9.68
SUPN's Price-to-Tangible-Book is ranked lower than
79% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. SUPN: 9.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SUPN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.86  Med: 7.57 Max: 19.49
Current: 9.68
3.86
19.49
Price-to-Intrinsic-Value-Projected-FCF 38.82
SUPN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
94% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. SUPN: 38.82 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SUPN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 33.22 Max: 38.97
Current: 38.82
0
38.97
Price-to-Median-PS-Value 1.11
SUPN's Price-to-Median-PS-Value is ranked higher than
53% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. SUPN: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SUPN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.94 Max: 11.48
Current: 1.11
0
11.48
Price-to-Graham-Number 3.01
SUPN's Price-to-Graham-Number is ranked lower than
55% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. SUPN: 3.01 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SUPN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0  Med: 4.02 Max: 8.71
Current: 3.01
0
8.71
Earnings Yield (Greenblatt) % 4.04
SUPN's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. SUPN: 4.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SUPN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1  Med: 3.1 Max: 5.5
Current: 4.04
1
5.5

More Statistics

Revenue (TTM) (Mil) $228.4
EPS (TTM) $ 1.83
Beta2.20
Short Percentage of Float7.99%
52-Week Range $17.25 - 34.35
Shares Outstanding (Mil)50.28
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Supernus to Host First Quarter 2017 Earnings Conference Call Apr 26 2017 
Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adol Apr 05 2017 
Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation Mar 07 2017 
Supernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation Mar 06 2017 
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
Pharma Stock With Triple-Digit Growth Forming Blotchy Base May 24 2017
Top 4 Pharmaceutical Stocks for 2017 May 19 2017
Want to Get in on Biotech? Check Out These 3 Stocks May 16 2017
Edited Transcript of SUPN earnings conference call or presentation 10-May-17 1:00pm GMT May 16 2017
Biotech Movers: Anika Up on Strong Analyst Ratings May 12 2017
Investor Network: Supernus Pharmaceuticals, Inc. to Host Earnings Call May 10 2017
Supernus misses Street 1Q forecasts May 09 2017
Supernus Announces First Quarter 2017 Financial Results May 09 2017
Supernus to Host First Quarter 2017 Earnings Conference Call Apr 26 2017
Harry Boxer’s momentum stocks to watch: 3 biotechs, 1 retailer Apr 19 2017
This Biotech Leader Breaks Out, Defying Sector Odds Apr 18 2017
Supernus Drug Gets Label Expansion for Migraines Apr 06 2017
Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and... Apr 05 2017
3 Highest Growth Stocks in the Market Today Mar 29 2017
Ultragenyxs’ Seizure Drug Fails Study Mar 23 2017
Supernus Pharma Tanks on Settlement of Two Patent Disputes (SUPN) Mar 08 2017
These Pharma Stocks Are Big Losers From Trump's Drug-Pricing Tweet Mar 07 2017
Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation Mar 07 2017
Supernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation Mar 06 2017
ETFs with exposure to Supernus Pharmaceuticals, Inc. : March 6, 2017 Mar 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat